CareDx Inc (CDNA)vsMerck & Company Inc (MRK)
CDNA
CareDx Inc
$79.81
-1.68%
HEALTHCARE · Cap: $4.59B
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 13446% more annual revenue ($67.38B vs $497.40M). CDNA leads profitability with a 25.9% profit margin vs 3.6%. CDNA trades at a lower P/E of 36.9x. CDNA earns a higher WallStSmart Score of 60/100 (C).
CDNA
Buy60
out of 100
Grade: C
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$65.83
Current Price
$79.81
$13.98 discount
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.3% year-over-year
Earnings expanding 1067.0% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.0x book value
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 25.9% and operating margin at 8.5%. Revenue growth of 39.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, Price/Book, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
CDNA profiles as a growth stock while MRK is a value play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.38 — expect wider price swings.
CDNA is growing revenue faster at 39.3% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
CDNA scores higher overall (60/100 vs 44/100), backed by strong 25.9% margins and 39.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?